Advertisement

Search Results

Advertisement



Your search for Simron Singh, MD matches 6 pages

Showing 1 - 6


issues in oncology

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Simron Singh, MD, MPH, of Sunnybrook Health Sciences Centre, discusses initial results of his data on a new patient experience measurement strategy used at Cancer Care Ontario.

solid tumors

Health-Related Quality of Life in Everolimus-Treated Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel and colleagues, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...

lung cancer
gastrointestinal cancer

Health-Related Quality of Life With Everolimus vs Placebo in Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel et al, no significant difference in deterioration of health-related quality of life was observed with everolimus (Afinitor) vs placebo in the phase III RADIANT-4 trial, which included patients with advanced nonfunctional well-differentiated...

neuroendocrine tumors

Everolimus Effective in Neuroendocrine Tumors of Gastrointestinal Origin

In a subgroup analysis of the phase III RADIANT-4 trial, focusing on neuroendocrine tumors of gastrointestinal origin, the mTOR inhibitor everolimus (Afinitor) essentially doubled the median progression-free survival time, compared with placebo, researchers reported at the 2016 Gastrointestinal...

gastroesophageal cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors of the GI tract and unknown primary (Abstract 315).

cns cancers

2016 GI Symposium: Everolimus Slows Growth of Neuroendocrine Tumors

Researchers report the results of a new analysis from a phase III trial of patients with neuroendocrine tumors that begin in the gastrointestinal (GI) tract or have an unknown origin. Compared to placebo, everolimus (Afinitor) was associated with a 6- to 8-month longer time period before the cancer ...

Advertisement

Advertisement



Advertisement